STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Corp. - INCY STOCK NEWS

Welcome to our dedicated news page for Incyte (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Incyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Incyte's position in the market.

News
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Rhea-AI Summary
Incyte announces the acquisition of Escient Pharmaceuticals, including their first-in-class oral MRGPR antagonists EP262 and EP547. The acquisition supports Incyte's portfolio strategy in Inflammation and Autoimmunity, enhancing their R&D activities. EP262 has shown promise in treating various inflammatory disorders, while EP547 targets cholestatic pruritus. The acquisition cost is $750 million with additional considerations, aiming to bring new treatment options to patients by leveraging Incyte's expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
acquisition
-
News
Incyte to Report First Quarter Financial Results
Rhea-AI Summary
Incyte (INCY) schedules first quarter financial results conference call and webcast on April 30, 2024, providing details for participation and access to replays.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences earnings
-
News
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Rhea-AI Summary
Incyte and China Medical System Holdings have entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib, a selective oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases in Asia. Incyte will receive upfront payment, potential milestones, and royalties, while CMS gains exclusive rights for development and commercialization in certain countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
News
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Incyte (INCY) granted equity inducement awards to the new Executive Vice President and General Manager of U.S. Dermatology, Matteo Trotta. The awards include 7,828 restricted stock units and stock options to purchase 21,868 shares of common stock. The RSUs vest over four years, while the stock options have a ten-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
News
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
Rhea-AI Summary
Incyte (INCY) announced positive results from a Phase 2 study on povorcitinib for prurigo nodularis treatment at AAD Annual Meeting. The study met primary and secondary endpoints, showing significant improvement in itch scores. Povorcitinib demonstrated potential as an effective treatment with well-tolerated safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
clinical trial
-
News
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
Rhea-AI Summary
Incyte (INCY) announces positive results from a Phase 2 study on ruxolitinib cream for hidradenitis suppurativa at AAD Annual Meeting. The study met its primary endpoint, demonstrating significant reduction in abscess and inflammatory nodule count compared to the vehicle control. Secondary endpoints also showed promising results, with a high percentage of patients achieving reductions in AN count. Ruxolitinib cream was well-tolerated with few adverse events. These results indicate the potential for ruxolitinib cream as an effective treatment option for patients with milder HS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
clinical trial
News
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Rhea-AI Summary
Incyte (INCY) announces multiple abstracts featuring data from its dermatology portfolio to be presented at the 2024 AAD Annual Meeting. Key highlights include ruxolitinib cream and povorcitinib studies in various dermatologic conditions. Late-breaking abstracts on prurigo nodularis and hidradenitis suppurativa to be presented. Analyst and investor event scheduled for March 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
News
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
Rhea-AI Summary
Incyte launches The Unseen Journey program using AI to visually depict the impact of myeloproliferative neoplasms (MPNs) on patients. The program transforms patient experiences into unique images to raise awareness and empathy for those with MPNs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
AI
-
News
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Rhea-AI Summary
Incyte's axatilimab receives Priority Review acceptance for chronic GVHD treatment after positive AGAVE-201 trial results, showing promising efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
News
Incyte to Present at Upcoming Investor Conference
Rhea-AI Summary
Incyte (INCY) to present at Cowen 44th Annual Health Care Conference on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
Stock INCY logo
Incyte Corp.

Nasdaq:INCY

INCY Rankings

#739 Ranked by Market Cap
#3820 Ranked by Stock Gains
N/A Ranked by Dividends

INCY Stock Data

12.09B
186.98M
1.58%
100.2%
3.59%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
US
Wilmington

About INCY

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.